Bemiparin

Bemiparin - a second generation, synthetic, low-molecular-weight heparin (lmwh) with anticoagulant activity. Derived, after depolymerisation and fractionation, from medical-grade porcine unfractionated heparin (ufh), bemiparin has an average molecular weight of 3,600 daltons and has a higher anti-factor xa/anti-factor iia ratio (8:1) than first-generation lmwhs. This anticoagulant binds to antithrombin iii, thereby enhancing the inactivation of activated factor x (factor xa) and, to a lesser extent, activated factor ii (factor iia). Compared to unfractionated heparins, the use of bemiparin is associated with lower incidences of major bleeding, osteoporosis, and heparin-induced thrombocytopenia. Bemiparin also promotes a greater release of tissue factor pathway inhibitor than ufh or dalteparin.

Resources

Latest articles - Bemiparin

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Bemiparin for any updates.

‎